APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tuberculosis (TB) Diagnostics

Tuberculosis (TB) is an infectious disease usually caused by the bacterium Mycobacterium tuberculosis (MTB). Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections do not have symptoms, in which case it is known as latent tuberculosis. About 10% of latent infections progress to active disease which, if left untreated, kills about half of those infected. The classic symptoms of active TB are a chronic cough with blood-containing sputum, fever, night sweats, and weight loss. The historical term "consumption" came about due to the weight loss. Infection of other organs can cause a wide range of symptoms.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Tuberculosis (TB) is an infectious disease usually caused by the bacterium Mycobacterium tuberculosis (MTB). Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections do not have symptoms, in which case it is known as latent tuberculosis. About 10% of latent infections progress to active disease which, if left untreated, kills about half of those infected. The classic symptoms of active TB are a chronic cough with blood-containing sputum, fever, night sweats, and weight loss. The historical term "consumption" came about due to the weight loss. Infection of other organs can cause a wide range of symptoms.

Selected research

Market Analysis & Forecast

Global Tuberculosis (TB) Diagnostics Market Analysis and Forecast 2026-2032

26 December 2025190 pages

Choose your research edition.

Industry ResearchTuberculosis (TB) Diagnostics Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Tuberculosis (TB) Diagnostics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Tuberculosis (TB) Diagnostics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tuberculosis (TB) Diagnostics Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Tuberculosis (TB) Diagnostics Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Tuberculosis (TB) is an infectious disease usually caused by the bacterium Mycobacterium tuberculosis (MTB). Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections do not have symptoms, in which case it is known as latent tuberculosis. About 10% of latent infections progress to active disease which, if left untreated, kills about half of those infected. The classic symptoms of active TB are a chronic cough with blood-containing sputum, fever, night sweats, and weight loss. The historical term "consumption" came about due to the weight loss. Infection of other organs can cause a wide range of symptoms.

Global Tuberculosis (TB) Diagnostics key players include Danaher, Roche, Thermo Fisher Scientific, BD, Abbott, etc. Global top five manufacturers hold a share about 33%.

APAC is the largest market, with a share over 40%, followed by Americas and Europe, both have a share about 40 percent.

Read the full market overview

In terms of product, Culture-based is the largest segment, with a share about 33%. And in terms of application, the largest application is Hospitals, followed by Diagnostic Laboratories.

Report Includes

This report presents an overview of global market for Tuberculosis (TB) Diagnostics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Tuberculosis (TB) Diagnostics, also provides the revenue of main regions and countries. Of the upcoming market potential for Tuberculosis (TB) Diagnostics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Tuberculosis (TB) Diagnostics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Tuberculosis (TB) Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Tuberculosis (TB) Diagnostics revenue, projected growth trends, production technology, application and end-user industry.

Tuberculosis (TB) Diagnostics Segment by Company

Danaher

Roche

Thermo Fisher Scientific

BD

Abbott

Hologic

Qiagen

BioMerieux

Hain Lifescience

Oxford Immunotec

Tuberculosis (TB) Diagnostics Segment by Type

Culture-Based Diagnostics

Sputum Smear Microscopy

Rapid Molecular Diagnostics

Others

Tuberculosis (TB) Diagnostics Segment by Application

Diagnostic Laboratories

Hospitals

Tuberculosis (TB) Diagnostics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis (TB) Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis (TB) Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis (TB) Diagnostics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Tuberculosis (TB) Diagnostics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Tuberculosis (TB) Diagnostics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Tuberculosis (TB) Diagnostics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Tuberculosis (TB) Diagnostics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Culture-Based Diagnostics Major Player Table 3. Sputum Smear Microscopy Major Player Table 4. Rapid Molecular Diagnostics Major Player Table 5. Others Major Player Table 6. Global Tuberculosis (TB) Diagnostics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Diagnostic Laboratories Major Player Table 8. Hospitals Major Player Table 9. Tuberculosis (TB) Diagnostics Industry Trends Table 10. Tuberculosis (TB) Diagnostics Industry Drivers Table 11. Tuberculosis (TB) Diagnostics Industry Opportunities and Challenges Table 12. Tuberculosis (TB) Diagnostics Industry Restraints Table 13. Global Tuberculosis (TB) Diagnostics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Tuberculosis (TB) Diagnostics Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Tuberculosis (TB) Diagnostics Market Share by Region (2021-2026) Table 16. Global Tuberculosis (TB) Diagnostics Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Tuberculosis (TB) Diagnostics Market Share by Region (2027-2032) Table 18. Global Tuberculosis (TB) Diagnostics Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Tuberculosis (TB) Diagnostics Revenue Market Share by Players (2021-2026) Table 20. Global Tuberculosis (TB) Diagnostics Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Tuberculosis (TB) Diagnostics Key Players Headquarters & Area Served Table 22. Global Tuberculosis (TB) Diagnostics Players, Product Type & Application Table 23. Global Tuberculosis (TB) Diagnostics Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Tuberculosis (TB) Diagnostics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Tuberculosis (TB) Diagnostics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Tuberculosis (TB) Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Tuberculosis (TB) Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Tuberculosis (TB) Diagnostics Revenue Market Share by Type (2021-2026) Table 30. Global Tuberculosis (TB) Diagnostics Revenue Market Share by Type (2027-2032) Table 31. Global Tuberculosis (TB) Diagnostics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Tuberculosis (TB) Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Tuberculosis (TB) Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Tuberculosis (TB) Diagnostics Revenue Market Share by Application (2021-2026) Table 35. Global Tuberculosis (TB) Diagnostics Revenue Market Share by Application (2027-2032) Table 36. Danaher Company Information Table 37. Danaher Business Overview Table 38. Danaher Tuberculosis (TB) Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Danaher Tuberculosis (TB) Diagnostics Product Portfolio Table 40. Danaher Recent Development Table 41. Roche Company Information Table 42. Roche Business Overview Table 43. Roche Tuberculosis (TB) Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Roche Tuberculosis (TB) Diagnostics Product Portfolio Table 45. Roche Recent Development Table 46. Thermo Fisher Scientific Company Information Table 47. Thermo Fisher Scientific Business Overview Table 48. Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Product Portfolio Table 50. Thermo Fisher Scientific Recent Development Table 51. BD Company Information Table 52. BD Business Overview Table 53. BD Tuberculosis (TB) Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. BD Tuberculosis (TB) Diagnostics Product Portfolio Table 55. BD Recent Development Table 56. Abbott Company Information Table 57. Abbott Business Overview Table 58. Abbott Tuberculosis (TB) Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Abbott Tuberculosis (TB) Diagnostics Product Portfolio Table 60. Abbott Recent Development Table 61. Hologic Company Information Table 62. Hologic Business Overview Table 63. Hologic Tuberculosis (TB) Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Hologic Tuberculosis (TB) Diagnostics Product Portfolio Table 65. Hologic Recent Development Table 66. Qiagen Company Information Table 67. Qiagen Business Overview Table 68. Qiagen Tuberculosis (TB) Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Qiagen Tuberculosis (TB) Diagnostics Product Portfolio Table 70. Qiagen Recent Development Table 71. BioMerieux Company Information Table 72. BioMerieux Business Overview Table 73. BioMerieux Tuberculosis (TB) Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. BioMerieux Tuberculosis (TB) Diagnostics Product Portfolio Table 75. BioMerieux Recent Development Table 76. Hain Lifescience Company Information Table 77. Hain Lifescience Business Overview Table 78. Hain Lifescience Tuberculosis (TB) Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Hain Lifescience Tuberculosis (TB) Diagnostics Product Portfolio Table 80. Hain Lifescience Recent Development Table 81. Oxford Immunotec Company Information Table 82. Oxford Immunotec Business Overview Table 83. Oxford Immunotec Tuberculosis (TB) Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Oxford Immunotec Tuberculosis (TB) Diagnostics Product Portfolio Table 85. Oxford Immunotec Recent Development Table 86. North America Tuberculosis (TB) Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 87. North America Tuberculosis (TB) Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 88. North America Tuberculosis (TB) Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 89. North America Tuberculosis (TB) Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 90. North America Tuberculosis (TB) Diagnostics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. North America Tuberculosis (TB) Diagnostics Revenue by Country (2021-2026) & (US$ Million) Table 92. North America Tuberculosis (TB) Diagnostics Revenue by Country (US$ Million) & (2027-2032) Table 93. Europe Tuberculosis (TB) Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 94. Europe Tuberculosis (TB) Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 95. Europe Tuberculosis (TB) Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 96. Europe Tuberculosis (TB) Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 97. Europe Tuberculosis (TB) Diagnostics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. Europe Tuberculosis (TB) Diagnostics Revenue by Country (2021-2026) & (US$ Million) Table 99. Europe Tuberculosis (TB) Diagnostics Revenue by Country (US$ Million) & (2027-2032) Table 100. China Tuberculosis (TB) Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 101. China Tuberculosis (TB) Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 102. China Tuberculosis (TB) Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 103. China Tuberculosis (TB) Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 104. Asia Tuberculosis (TB) Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 105. Asia Tuberculosis (TB) Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 106. Asia Tuberculosis (TB) Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 107. Asia Tuberculosis (TB) Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 108. Asia Tuberculosis (TB) Diagnostics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 109. Asia Tuberculosis (TB) Diagnostics Revenue by Region (US$ Million) & (2021-2026) Table 110. Asia Tuberculosis (TB) Diagnostics Revenue by Region (US$ Million) & (2027-2032) Table 111. SAMEA Tuberculosis (TB) Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 112. SAMEA Tuberculosis (TB) Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 113. SAMEA Tuberculosis (TB) Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 114. SAMEA Tuberculosis (TB) Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 115. SAMEA Tuberculosis (TB) Diagnostics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. SAMEA Tuberculosis (TB) Diagnostics Revenue by Country (2021-2026) & (US$ Million) Table 117. SAMEA Tuberculosis (TB) Diagnostics Revenue by Country (US$ Million) & (2027-2032) Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Tuberculosis (TB) Diagnostics Image Figure 2. Global Tuberculosis (TB) Diagnostics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tuberculosis (TB) Diagnostics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Culture-Based Diagnostics Image Figure 5. Sputum Smear Microscopy Image Figure 6. Rapid Molecular Diagnostics Image Figure 7. Others Image Figure 8. Global Tuberculosis (TB) Diagnostics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Tuberculosis (TB) Diagnostics Market Size Share 2021 VS 2025 VS 2032 Figure 10. Diagnostic Laboratories Image Figure 11. Hospitals Image Figure 12. Global Tuberculosis (TB) Diagnostics Market Size (US$ Million) & (2021-2032) Figure 13. Global Tuberculosis (TB) Diagnostics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Tuberculosis (TB) Diagnostics Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Tuberculosis (TB) Diagnostics Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Tuberculosis (TB) Diagnostics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Tuberculosis (TB) Diagnostics Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Tuberculosis (TB) Diagnostics Revenue Market Share by Type (2021-2032) Figure 20. Global Tuberculosis (TB) Diagnostics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Tuberculosis (TB) Diagnostics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Tuberculosis (TB) Diagnostics Revenue Market Share by Application (2021-2032) Figure 23. North America Tuberculosis (TB) Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Tuberculosis (TB) Diagnostics Revenue Share by Type (2021-2032) Figure 25. North America Tuberculosis (TB) Diagnostics Revenue Share by Application (2021-2032) Figure 26. North America Tuberculosis (TB) Diagnostics Revenue Share by Country (2021-2032) Figure 27. United States Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Tuberculosis (TB) Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Tuberculosis (TB) Diagnostics Revenue Share by Type (2021-2032) Figure 32. Europe Tuberculosis (TB) Diagnostics Revenue Share by Application (2021-2032) Figure 33. Europe Tuberculosis (TB) Diagnostics Revenue Share by Country (2021-2032) Figure 34. Germany Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Tuberculosis (TB) Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Tuberculosis (TB) Diagnostics Revenue Share by Type (2021-2032) Figure 44. China Tuberculosis (TB) Diagnostics Revenue Share by Application (2021-2032) Figure 45. Asia Tuberculosis (TB) Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Tuberculosis (TB) Diagnostics Revenue Share by Type (2021-2032) Figure 47. Asia Tuberculosis (TB) Diagnostics Revenue Share by Application (2021-2032) Figure 48. Asia Tuberculosis (TB) Diagnostics Revenue Share by Region (2021-2032) Figure 49. Japan Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Tuberculosis (TB) Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Tuberculosis (TB) Diagnostics Revenue Share by Type (2021-2032) Figure 57. SAMEA Tuberculosis (TB) Diagnostics Revenue Share by Application (2021-2032) Figure 58. SAMEA Tuberculosis (TB) Diagnostics Revenue Share by Country (2021-2032) Figure 59. Brazil Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Tuberculosis (TB) Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Culture-Based Diagnostics
  • Sputum Smear Microscopy
  • Rapid Molecular Diagnostics
  • Others
Applications
  • Diagnostic Laboratories
  • Hospitals
Companies covered
  • Danaher
  • Roche
  • Thermo Fisher Scientific
  • BD
  • Abbott
  • Hologic
  • Qiagen
  • BioMerieux
  • Hain Lifescience
  • Oxford Immunotec

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Tuberculosis (TB) Diagnostics Market by Type
  3. 1.2.1 Global Tuberculosis (TB) Diagnostics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Culture-Based Diagnostics
  5. 1.2.3 Sputum Smear Microscopy
  6. 1.2.4 Rapid Molecular Diagnostics
  7. 1.2.5 Others
  8. 1.3 Tuberculosis (TB) Diagnostics Market by Application
  9. 1.3.1 Global Tuberculosis (TB) Diagnostics Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Diagnostic Laboratories
  11. 1.3.3 Hospitals
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Tuberculosis (TB) Diagnostics Market Dynamics
  1. 2.1 Tuberculosis (TB) Diagnostics Industry Trends
  2. 2.2 Tuberculosis (TB) Diagnostics Industry Drivers
  3. 2.3 Tuberculosis (TB) Diagnostics Industry Opportunities and Challenges
  4. 2.4 Tuberculosis (TB) Diagnostics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Tuberculosis (TB) Diagnostics Market Perspective (2021-2032)
  2. 3.2 Global Tuberculosis (TB) Diagnostics Growth Trends by Region
  3. 3.2.1 Global Tuberculosis (TB) Diagnostics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Tuberculosis (TB) Diagnostics Market Size by Region (2021-2026)
  5. 3.2.3 Global Tuberculosis (TB) Diagnostics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Tuberculosis (TB) Diagnostics Revenue by Players
  2. 4.1.1 Global Tuberculosis (TB) Diagnostics Revenue by Players (2021-2026)
  3. 4.1.2 Global Tuberculosis (TB) Diagnostics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Tuberculosis (TB) Diagnostics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Tuberculosis (TB) Diagnostics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Tuberculosis (TB) Diagnostics Key Players Headquarters & Area Served
  7. 4.4 Global Tuberculosis (TB) Diagnostics Players, Product Type & Application
  8. 4.5 Global Tuberculosis (TB) Diagnostics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Tuberculosis (TB) Diagnostics Market CR5 and HHI
  11. 4.6.3 2025 Tuberculosis (TB) Diagnostics Tier 1, Tier 2, and Tier 3
5 Tuberculosis (TB) Diagnostics Market Size by Type
  1. 5.1 Global Tuberculosis (TB) Diagnostics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Tuberculosis (TB) Diagnostics Revenue by Type (2021-2032)
  3. 5.3 Global Tuberculosis (TB) Diagnostics Revenue Market Share by Type (2021-2032)
6 Tuberculosis (TB) Diagnostics Market Size by Application
  1. 6.1 Global Tuberculosis (TB) Diagnostics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Tuberculosis (TB) Diagnostics Revenue by Application (2021-2032)
  3. 6.3 Global Tuberculosis (TB) Diagnostics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Danaher
  2. 7.1.1 Danaher Company Information
  3. 7.1.2 Danaher Business Overview
  4. 7.1.3 Danaher Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Danaher Tuberculosis (TB) Diagnostics Product Portfolio
  6. 7.1.5 Danaher Recent Developments
  7. 7.2 Roche
  8. 7.2.1 Roche Company Information
  9. 7.2.2 Roche Business Overview
  10. 7.2.3 Roche Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Roche Tuberculosis (TB) Diagnostics Product Portfolio
  12. 7.2.5 Roche Recent Developments
  13. 7.3 Thermo Fisher Scientific
  14. 7.3.1 Thermo Fisher Scientific Company Information
  15. 7.3.2 Thermo Fisher Scientific Business Overview
  16. 7.3.3 Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Product Portfolio
  18. 7.3.5 Thermo Fisher Scientific Recent Developments
  19. 7.4 BD
  20. 7.4.1 BD Company Information
  21. 7.4.2 BD Business Overview
  22. 7.4.3 BD Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 BD Tuberculosis (TB) Diagnostics Product Portfolio
  24. 7.4.5 BD Recent Developments
  25. 7.5 Abbott
  26. 7.5.1 Abbott Company Information
  27. 7.5.2 Abbott Business Overview
  28. 7.5.3 Abbott Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Abbott Tuberculosis (TB) Diagnostics Product Portfolio
  30. 7.5.5 Abbott Recent Developments
  31. 7.6 Hologic
  32. 7.6.1 Hologic Company Information
  33. 7.6.2 Hologic Business Overview
  34. 7.6.3 Hologic Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Hologic Tuberculosis (TB) Diagnostics Product Portfolio
  36. 7.6.5 Hologic Recent Developments
  37. 7.7 Qiagen
  38. 7.7.1 Qiagen Company Information
  39. 7.7.2 Qiagen Business Overview
  40. 7.7.3 Qiagen Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Qiagen Tuberculosis (TB) Diagnostics Product Portfolio
  42. 7.7.5 Qiagen Recent Developments
  43. 7.8 BioMerieux
  44. 7.8.1 BioMerieux Company Information
  45. 7.8.2 BioMerieux Business Overview
  46. 7.8.3 BioMerieux Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 BioMerieux Tuberculosis (TB) Diagnostics Product Portfolio
  48. 7.8.5 BioMerieux Recent Developments
  49. 7.9 Hain Lifescience
  50. 7.9.1 Hain Lifescience Company Information
  51. 7.9.2 Hain Lifescience Business Overview
  52. 7.9.3 Hain Lifescience Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Hain Lifescience Tuberculosis (TB) Diagnostics Product Portfolio
  54. 7.9.5 Hain Lifescience Recent Developments
  55. 7.10 Oxford Immunotec
  56. 7.10.1 Oxford Immunotec Company Information
  57. 7.10.2 Oxford Immunotec Business Overview
  58. 7.10.3 Oxford Immunotec Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Oxford Immunotec Tuberculosis (TB) Diagnostics Product Portfolio
  60. 7.10.5 Oxford Immunotec Recent Developments
8 North America
  1. 8.1 North America Tuberculosis (TB) Diagnostics Revenue (2021-2032)
  2. 8.2 North America Tuberculosis (TB) Diagnostics Revenue by Type (2021-2032)
  3. 8.2.1 North America Tuberculosis (TB) Diagnostics Revenue by Type (2021-2026)
  4. 8.2.2 North America Tuberculosis (TB) Diagnostics Revenue by Type (2027-2032)
  5. 8.3 North America Tuberculosis (TB) Diagnostics Revenue Share by Type (2021-2032)
  6. 8.4 North America Tuberculosis (TB) Diagnostics Revenue by Application (2021-2032)
  7. 8.4.1 North America Tuberculosis (TB) Diagnostics Revenue by Application (2021-2026)
  8. 8.4.2 North America Tuberculosis (TB) Diagnostics Revenue by Application (2027-2032)
  9. 8.5 North America Tuberculosis (TB) Diagnostics Revenue Share by Application (2021-2032)
  10. 8.6 North America Tuberculosis (TB) Diagnostics Revenue by Country
  11. 8.6.1 North America Tuberculosis (TB) Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Tuberculosis (TB) Diagnostics Revenue by Country (2021-2026)
  13. 8.6.3 North America Tuberculosis (TB) Diagnostics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Tuberculosis (TB) Diagnostics Revenue (2021-2032)
  2. 9.2 Europe Tuberculosis (TB) Diagnostics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Tuberculosis (TB) Diagnostics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Tuberculosis (TB) Diagnostics Revenue by Type (2027-2032)
  5. 9.3 Europe Tuberculosis (TB) Diagnostics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Tuberculosis (TB) Diagnostics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Tuberculosis (TB) Diagnostics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Tuberculosis (TB) Diagnostics Revenue by Application (2027-2032)
  9. 9.5 Europe Tuberculosis (TB) Diagnostics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Tuberculosis (TB) Diagnostics Revenue by Country
  11. 9.6.1 Europe Tuberculosis (TB) Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Tuberculosis (TB) Diagnostics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Tuberculosis (TB) Diagnostics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Tuberculosis (TB) Diagnostics Revenue (2021-2032)
  2. 10.2 China Tuberculosis (TB) Diagnostics Revenue by Type (2021-2032)
  3. 10.2.1 China Tuberculosis (TB) Diagnostics Revenue by Type (2021-2026)
  4. 10.2.2 China Tuberculosis (TB) Diagnostics Revenue by Type (2027-2032)
  5. 10.3 China Tuberculosis (TB) Diagnostics Revenue Share by Type (2021-2032)
  6. 10.4 China Tuberculosis (TB) Diagnostics Revenue by Application (2021-2032)
  7. 10.4.1 China Tuberculosis (TB) Diagnostics Revenue by Application (2021-2026)
  8. 10.4.2 China Tuberculosis (TB) Diagnostics Revenue by Application (2027-2032)
  9. 10.5 China Tuberculosis (TB) Diagnostics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Tuberculosis (TB) Diagnostics Revenue (2021-2032)
  2. 11.2 Asia Tuberculosis (TB) Diagnostics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Tuberculosis (TB) Diagnostics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Tuberculosis (TB) Diagnostics Revenue by Type (2027-2032)
  5. 11.3 Asia Tuberculosis (TB) Diagnostics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Tuberculosis (TB) Diagnostics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Tuberculosis (TB) Diagnostics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Tuberculosis (TB) Diagnostics Revenue by Application (2027-2032)
  9. 11.5 Asia Tuberculosis (TB) Diagnostics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Tuberculosis (TB) Diagnostics Revenue by Country
  11. 11.6.1 Asia Tuberculosis (TB) Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Tuberculosis (TB) Diagnostics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Tuberculosis (TB) Diagnostics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Tuberculosis (TB) Diagnostics Revenue (2021-2032)
  2. 12.2 SAMEA Tuberculosis (TB) Diagnostics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Tuberculosis (TB) Diagnostics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Tuberculosis (TB) Diagnostics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Tuberculosis (TB) Diagnostics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Tuberculosis (TB) Diagnostics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Tuberculosis (TB) Diagnostics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Tuberculosis (TB) Diagnostics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Tuberculosis (TB) Diagnostics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Tuberculosis (TB) Diagnostics Revenue by Country
  11. 12.6.1 SAMEA Tuberculosis (TB) Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Tuberculosis (TB) Diagnostics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Tuberculosis (TB) Diagnostics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst